A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine

Journal of Neurochemistry

Volumn 103, Issue 3, 2007, Pages 1219-1227

  Eyerman, David J ^a   Yamamoto, Bryan K ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Methamphetamine; Nitric oxide; Vesicle; Vesicular monoamine transporter 2

Indexed keywords

CYSTEINE DERIVATIVE; DOPAMINE; METHAMPHETAMINE; NITRIC OXIDE SYNTHASE; S METHYLTHIOCITRULLINE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL FRACTIONATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FUNCTIONAL PROTEOMICS; IMMUNOREACTIVITY; MALE; NERVE FIBER; NEUROTOXICITY; NITROSYLATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SYNAPTOSOME;

AMPHETAMINE; AMPHETAMINE-RELATED DISORDERS; ANIMALS; BRAIN; BUFFERS; CORPUS STRIATUM; CYTOSOL; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; MALE; NITRIC OXIDE SYNTHASE TYPE I; OXIDATION-REDUCTION; OXIDATIVE STRESS; PRESYNAPTIC TERMINALS; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTOSOMES; VESICULAR MONOAMINE TRANSPORT PROTEINS;

ANIMALIA;

EID: 35248900341     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.04837.x     Document Type: Article

References (55)

1. Abekawa T., Ohmori T. Koyama T. (1994) Effects of repeated administration of a high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens. Brain Res. 643, 276 281.
2. Abekawa T., Ohmori T. Koyama T. (1996) Effects of nitric oxide synthesis inhibition on methamphetamine-induced dopaminergic and serotonergic neurotoxicity in the rat brain. J. Neural Transm. 103, 671 680.
3. Ali S. F., Imam S. Z. Itzhak Y. (2005) Role of peroxynitrite in methamphetamine-induced dopaminergic neurodegeneration and neuroprotection by antioxidants and selective NOS inhibitors. Ann. NY Acad. Sci. 1053, 97 98.
4. Anderson K. L. Itzhak Y. (2006) Methamphetamine-induced selective dopaminergic neurotoxicity is accompanied by an increase in striatal nitrate in the mouse. Ann. NY Acad. Sci. 1074, 225 233.
5. Brown J. M., Hanson G. R. Fleckenstein A. E. (2000) Methamphetamine rapidly decreases vesicular dopamine uptake. J. Neurochem. 74, 2221 2223.
6. Brown J. M., Hanson G. R. Fleckenstein A. E. (2001) Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J. Pharmacol. Exp. Ther. 296, 762 767.
7. Brown J. M., Quinton M. S. Yamamoto B. K. (2005) Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite. J. Neurochem. 95, 429 436.
8. Burrows K. B., Nixdorf W. L. Yamamoto B. K. (2000) Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines. J. Pharmacol. Exp. Ther. 292, 853 860.
9. Cubells J. F., Rayport S, Rajendran G Sulzer D. (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14, 2260 2271.
10. Darvesh A. S., Yamamoto B. K. Gudelsky G. A. (2005) Evidence for the involvement of nitric oxide in 3,4-methylenedioxymethamphetamine-induced serotonin depletion in the rat brain. J. Pharmacol. Exp. Ther. 312, 694 701.
11. Davies K. J. (2001) Degradation of oxidized proteins by the 20S proteasome. Biochimie 83, 301 310.
12. Di Monte D. A., Royland J. E., Jakowec M. W. Langston J. W. (1996) Role of nitric oxide in methamphetamine neurotoxicity: protection by 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase. J. Neurochem. 67, 2443 2450.
13. Dunlop R. A., Rodgers K. J. Dean R. T. (2002) Recent developments in the intracellular degradation of oxidized proteins. Free Radic. Biol. Med. 33, 894 906.
14. Eyerman D. J. Yamamoto B. K. (2005) Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. J. Pharmacol. Exp. Ther. 312, 160 169.
15. Fleckenstein A. E., Gibb J. W. Hanson G. R. (2000) Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur. J. Pharmacol. 406, 1 13.
16. Fleckenstein A. E., Volz T. J., Riddle E. L., Gibb J. W. Hanson G. R. (2007) New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 47, 681 698.
17. Frey K., Kilbourn M. Robinson T. (1997) Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur. J. Pharmacol. 334, 273 279.
18. Fumagalli F, Gainetdinov R. R., Wang Y. M., Valenzano K. J., Miller G. W. Caron M. G. (1999) Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 19, 2424 2431.
19. Furfine E. S., Harmon M. F., Paith J. E., Knowles R. G., Salter M, Kiff R. J., Duffy C, Hazelwood R, Oplinger J. A. Garvey E. P. (1994) Potent and selective inhibition of human nitric oxide synthases. Selective inhibition of neuronal nitric oxide synthase by S-methyl-L-thiocitrulline and S-ethyl-L-thiocitrulline. J. Biol. Chem. 269, 26677 26683.
20. Garthwaite J. (1991) Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci. 14, 60 67.
21. Gibb J. W. Kogan F. J. (1979) Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase activity. Naunyn Schmiedebergs Arch. Pharmacol. 310, 185 187.
22. Gow A. J., Duran D, Malcolm S Ischiropoulos H. (1996) Effects of peroxynitrite-induced protein modifications on tyrosine phosphorylation and degradation. FEBS Lett. 385, 63 66.
23. Gow A. J., Buerk D. G. Ischiropoulos H. (1997) A novel reaction mechanism for the formation of S-nitrosothiol in vivo. J. Biol. Chem. 272, 2841 2845.
24. Hogan K. A., Staal R. G. Sonsalla P. K. (2000) Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J. Neurochem. 74, 2217 2220.
25. Imam S. Z., Crow J. P., Newport G. D., Islam F, Slikker W. Jr. Ali S. F. (1999) Methamphetamine generates peroxynitrite and produces dopaminergic neurotoxicity in mice: protective effects of peroxynitrite decomposition catalyst. Brain Res. 837, 15 21.
26. Imam S. Z., el-Yazal J, Newport G. D., Itzhak Y, Cadet J. L., Slikker W. Jr. Ali S. F. (2001a) Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. Ann. NY Acad. Sci. 939, 366 380.
27. Imam S. Z., Newport G. D., Itzhak Y, Cadet J. L., Islam F, Slikker W. Jr. Ali S. F. (2001b) Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J. Neurochem. 76, 745 749.
28. Itzhak Y Ali S. F. (1996) The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo. J. Neurochem. 67, 1770 1773.
29. Itzhak Y Ali S. F. (2006) Role of nitrergic system in behavioral and neurotoxic effects of amphetamine analogs. Pharmacol. Ther. 109, 246 262.
30. Itzhak Y, Martin J. L. Ail S. F. (2000) nNOS inhibitors attenuate methamphetamine-induced dopaminergic neurotoxicity but not hyperthermia in mice. Neuroreport 11, 2943 2946.
31. Kogan F. J., Nichols W. K. Gibb J. W. (1976) Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur. J. Pharmacol. 36, 363 371.
32. Kokoshka J. M., Vaughan R. A., Hanson G. R. Fleckenstein A. E. (1998) Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur. J. Pharmacol. 361, 269 275.
33. Kuhn D. M. Arthur R. E. Jr. (1997) Inactivation of tryptophan hydroxylase by nitric oxide: enhancement by tetrahydrobiopterin. J. Neurochem. 68, 1495 1502.
34. Kuhn D. M. Geddes T. J. (1999) Peroxynitrite inactivates tryptophan hydroxylase via sulfhydryl oxidation. Coincident nitration of enzyme tyrosyl residues has minimal impact on catalytic activity. J. Biol. Chem. 274, 29726 29732.
35. Kuhn D. M. Geddes T. J. (2000) Molecular footprints of neurotoxic amphetamine action. Ann. NY Acad. Sci. 914, 92 103.
36. Larsen K. E., Fon E. A., Hastings T. G., Edwards R. H. Sulzer D. (2002) Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci. 22, 8951 8960.
37. LaVoie M. J. Hastings T. G. (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19, 1484 1491.
38. Metzger R. R., Brown J. M., Sandoval V, Rau K. S., Elwan M. A., Miller G. W., Hanson G. R. Fleckenstein A. E. (2002) Inhibitory effect of reserpine on dopamine transporter function. Eur. J. Pharmacol. 456, 39 43.
39. Nash J. F. Yamamoto B. K. (1992) Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res. 581, 237 243.
40. Park S. U., Ferrer J. V., Javitch J. A. Kuhn D. M. (2002) Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons. J. Neurosci. 22, 4399 4405.
41. Reagan L. P., Magarin̂os A. M., Yee D. K., Swzeda L. I., Van Bueren A., McCall A. L. McEwen B. S. (2000) Oxidative stress and HNE conjugation of GLUT3 are increased in the hippocampus of diabetic rats subjected to stress. Brain Res. 862, 292 300.
42. Ricaurte G. A., Guillery R. W., Seiden L. S., Schuster C. R. Moore R. Y. (1982) Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235, 93 103.
43. Riddle E. L., Topham M. K., Haycock J. W., Hanson G. R. Fleckenstein A. E. (2002) Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur. J. Pharmacol. 449, 71 74.
44. Sadidi M, Geddes T. J. Kuhn D. M. (2005) S-thiolation of tyrosine hydroxylase by reactive nitrogen species in the presence of cysteine or glutathione. Antioxid. Redox Signal. 7, 863 869.
45. Sandoval V, Riddle E. L., Hanson G. R. Fleckenstein A. E. (2003) Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J. Pharmacol. Exp. Ther. 304, 1181 1187.
46. Seiden L. S. (1985) Methamphetamine: toxicity to dopaminergic neurons. NIDA Res. Monogr. 62, 100 116.
47. Stamler J. S. Hausladen A. (1998) Oxidative modifications in nitrosative stress. Nat. Struct. Biol. 5, 247 249.
48. Staszewski R. D. Yamamoto B. K. (2006) Methamphetamine-induced spectrin proteolysis in the rat striatum. J. Neurochem. 96, 1267 1276.
49. Stephans S. E. Yamamoto B. K. (1994) Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse 17, 203 209.
50. Thiriot D. S. Ruoho A. E. (2001) Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport. J. Biol. Chem. 276, 27304 27315.
51. Thiriot D. S., Sievert M. K. Ruoho A. E. (2002) Identification of human vesicle monoamine transporter (VMAT2) lumenal cysteines that form an intramolecular disulfide bond. Biochemistry 41, 6346 6353.
52. Wagner G. C., Seiden L. S. Schuster C. R. (1979) Methamphetamine-induced changes in brain catecholamines in rats and guinea pigs. Drug Alcohol Depend. 4, 435 438.
53. Wagner G. C., Ricaurte G. A., Seiden L. S., Schuster C. R., Miller R. J. Westley J. (1980) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181, 151 160.
54. Wagner G. C., Lucot J. B., Schuster C. R. Seiden L. S. (1983) Alpha-methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes. Brain Res. 270, 285 288.
55. Yamamoto B. K. Zhu W. (1998) The effects of methamphetamine on the production of free radicals and oxidative stress. J. Pharmacol. Exp. Ther. 287, 107 114.